Summary ODC-OT-Galleri 050124
Written by Lisbeth Roy
Updated at February 20th, 2025
| RGCC Oncotrace | RGCC Onco-D-clare | Galleri |
| Liquid Biopsy | Liquid Biopsy | Liquid Biopsy |
|
For established cancer diagnosis or anyone with a history of cancer or cancer in remission, and cancer surveillance to detect recurrence |
For healthy population, with no history of cancer, but with risks due to family history or vulnerability from environmental toxin exposure |
For healthy population, with no history of cancer, but with risks due to family history or vulnerability from environmental toxin exposure |
| Symptomatic or asymptomatic | Symptomatic or asymptomatic | Symptomatic or asymptomatic |
| Detection of cancer activity by presence of CTCs (circulating tumor cells) |
Earlier detection than Oncotrace; early detection of cancer does not depend on cfDNA fragments |
Early detection of cancer is dependent on release of cfDNA fragments |
|
Screens for CTCs by isolating from blood cells (WBCs, RBCs); CTCs are a subpopulation in PBMCs (peripheral blood mononuclear cells) |
Screens for cancer by gene expression profile analysis of PBMCs, which consists of lymphocytes and monocytes in peripheral blood |
Screens for cancer by detecting cell- free DNA fragments (from body cells including cancer cells) in peripheral blood |
|
Discriminates subpopulations of CTCs (CSCs or cancer stem cells), tissue of origin (limited by availability of CTC surface biomarkers), and determines prognosis and risks |
Discriminates between CANCER and HEALTHY state | Discriminates between CANCER and HEALTHY state |
| CTC screening | Cancer screening | Cancer screening |
| Method is negative selection using fluidic-based immunomagnetic beads with flow cytometry, to separate CTCs from WBCs and RBCs | Method is qRT-PCR for PBMCs gene expression clustering analysis using hierarchical and k-means algorithms with AI |
Method is Next Generation Sequencing (NGS) and machine- learning algorithms (AI) identifying cancer signal by the methylation patterns found on cell-free DNA (cfDNA) |
| True positive 86.2% | True positive 92.40% |
True positive 51.5% (all cancers across all stages, 76.3% for 12 deadly cancer classes) |
| True negative 83.9% | True negative 94.78% | True negative 99.5% |